NEPH

The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on personnel changes and compensation arrangements.

Material Changes

Appointment of CEO: Andrew Astor, currently the Chief Financial Officer (CFO) and Chief Operating Officer (COO), was appointed President and Chief Executive Officer (CEO).
Role Consolidation: Mr. Astor will serve as both CEO and CFO until a new CFO is hired. The COO position will remain vacant.
Board Appointment: Mr. Astor will join the Board of Directors as a Class III director.
Departure of CEO: Daron Evans will step down as President, CEO, and Board member. He will remain CEO of the subsidiary Specialty Renal Products, Inc. and serve as a special advisor.

Compensation and Outlook

Compensation for Andrew Astor:

Base Salary: $325,000 annually.
Performance Bonus: Targeted at 30% of annualized base salary.
Equity Grant: 10-year stock option for 152,064 shares. Vesting is 25% on the first anniversary, with the remaining 75% vesting in quarterly installments.
Severance: In the event of termination without "cause" or resignation for "good reason," Mr. Astor is entitled to 12 months of base salary and 6 months of health benefits.

Management Commentary: Mr. Evans' resignation was not the result of any disagreement with the Company regarding operations, policies, or practices.

Investor Verification Checklist

Verify the exact closing stock price on August 24, 2020, to determine the exercise price of Mr. Astor's stock options.
Confirm the timeline for the recruitment of a new Chief Financial Officer.
Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership transition.
Monitor future filings for the formal employment agreement between the Company and Mr. Astor.